Developing Deep and Comprehensive Portfolio of NCEs and Other Innovative Solutions
Our robust pipeline features novel chemical entities (NCEs) with strong
intellectual property protection, targeting critical unmet medical needs
in addiction treatment and beyond.
Issued Patent Protection into the mid 2040s Anchored by Composition-of-Matter Patents
SOPH-110S
Composition of Matter is covered by U.S. Patent No. 11,649,208, which expires November 30, 2041, subject to patent term extension
Foreign applications pending in Australia, Canada, China, Eurasia (Russia), Europe, Israel, India, Japan, South Korea, and New Zealand
Co-crystal Form is covered by U.S. Patent No. 12,171,753, which expires June 28, 2042
Foreign applications pending in China, Europe, and Japan
DETC-MeSO
Covered by U.S. Patent No. 11,746,089, which expires November 30, 2041, subject to patent term extension
Foreign applications pending in Australia, Canada, China, Eurasia (Russia), Europe, Israel, India, Japan, South Korea, and New Zealand
Co-crystal Form is covered by U.S. Patent No. 12,171,753, which expires June 28, 2042
Foreign applications pending in China, Europe, and Japan
Provisional application pending related to conjugates of DETC-MeSO analogs with anti-abuse agents
Fillings in process for SOPH123 by end of year
Additional filings planned for new indications, pharmaceutical formulations, PK/PD profiles, etc.
Interested in more information on partnership or licensing opportunities?
